Skip to main content
OCS logo

Oculis Holding AG (OCS) Stock: Price, Forecast & Analyst Target

Oculis Holding AG (OCS) — MoonshotScore 23/100 (Weak band), calculated Oct 5, 2026. Price $8.56 (-1.95%), as of the Oct 5, 2026 trading session; market cap $489M.

Educational signal · not a buy or sell recommendation · How to read this

$8.56 −$0.17 (-1.95%) Market Cap $489M

Oculis Holding AG · OCS · NASDAQ

Oculis Holding AG is a clinical-stage biopharmaceutical company specializing in topical ophthalmic treatments.

Price as of Oct 5, 2026

Key Statistics

23 of 100

MoonshotScore v2 · Oculis Holding AG (OCS)

Weak
Business Quality Thin (20)
Financial Safety Sound (78)
Valuation Rich (39)
Growth Durability Shrinking (8)
Momentum Falling (19)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A strong balance sheet, but bottom-tier quality and stalling growth, and the price trend has turned against it. Business Quality: Thin; Financial Safety: Sound; Valuation: Rich; Growth Durability: Shrinking; Momentum: Falling.

  • quarterly revenue $292,236.66 (Q3 FY2025, quarter ended Sep 30, 2025)
  • EPS beat 2 of 8
  • Altman Z 5.58 · Piotroski F 4

Holding back: weak fundamentals, soft growth, weak price trend

Helping: balance-sheet strength

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for OCS (29 recorded, newest six shown)
RecordedScoreBand
23Weak
23Weak
23Weak
23Weak
23Weak
23Weak

The score was 23 in the stored Oct 4, 2026 snapshot and remains 23 in the current publication computed Oct 5, 2026 (0); the largest pillar moves were Financial Safety +1 and Growth Durability +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$8.56
Change on the day-1.95%
52-week range$9.00 – $34.48
Market capitalisation$489M
Shares traded on the day242.0K

Price & events

Other perspectives

Council score for Oculis Holding AG (OCS): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

9-Factor Breakdown

Revenue Growth Neutral
Gross Margin Weak
Operating Leverage Neutral
Cash Runway Neutral
R&D Intensity Neutral
Insider Activity Moderate
Trading Liquidity Neutral
Price Momentum Negative
News Sentiment Neutral

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Sep 7, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Negative
ROE Negative
Gross Margin Negative

Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Oct 5, 2026, except a card that shows its own read date.

Watch the OCS film — every key number, told as a short cinematic story

~2 min · open the film

1 · What is it?

What is Oculis Holding AG (OCS), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Oculis Holding AG (OCS) is listed on NASDAQ. It employs 60 people and is led by Riad Sherif. In Q3 FY2025 it reported revenue of $292,236.66 and net income of -$20M. The market values it at $489M.

2 · Latest results

What do the latest results show for Oculis Holding AG (OCS)?

Short answer · as of

The most recent reported quarter, Q3 FY2025, carried revenue of $292,236.66. Against analyst estimates the company has EPS beat 2 of 8 reports.

Quarterly income statement — 1 quarters
Revenue, net income and earnings per share by quarter (converted from CHF)
PeriodRevenueNet incomeEPS
Q3 FY2025$292,236.66-$20M-$0.38 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Oculis Holding AG (OCS)?

Short answer

The MoonshotScore pillars rate balance-sheet strength as strengths. What is holding it back is weak fundamentals, soft growth, weak price trend. The distress and quality screens read Altman Z 5.58 · Piotroski F 4. Trailing ratios: ROE -42.9% · ROA -31.8% · current ratio 8.35 · earnings yield -15.1% · free-cash-flow yield -13.4%.

Data-derived red flags

  • Negative return on equity (-42.9%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
4 · What to check next?

What should you watch next at Oculis Holding AG (OCS)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $862,272 · EPS -1.55 · 7 analysts. Current published price targets run low $26.00 · high $45.00 · consensus $36.75 · median $38.00 against a quoted price of $8.56 (as of Oct 5, 2026).

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • The newest quarter held here (Q3 FY2025) was filed Sep 30, 2025 — 12 months ago.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Oculis Holding AG compare with its peers?

Short answer

Oculis Holding AG's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Eli Lilly and Company (LLY) Named competitor$1143.12 Oct 5, 2026$1.08T97 5-pillar Oct 5, 2026
Theravance Biopharma, Inc. (TBPH) Same industry, near in market value$17.03 Sep 23, 2026$883M95 5-pillar Oct 5, 2026
CorMedix Inc. (CRMD) Same industry, near in market value$7.26 Oct 5, 2026$571M94 5-pillar Oct 5, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$47.79 Oct 5, 2026$872M93 5-pillar Oct 5, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$10.70 Oct 5, 2026$591M91 5-pillar Oct 5, 2026
MiMedx Group, Inc. (MDXG) Same industry, near in market value$4.55 Oct 5, 2026$669M88 5-pillar Oct 5, 2026
Arbutus Biopharma Corporation (ABUS) Same industry, near in market value$4.67 Oct 5, 2026$923M85 5-pillar Oct 5, 2026
Novartis AG (NVS) Named competitor$140.93 Oct 5, 2026$267B84 5-pillar Oct 5, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$9.80 Oct 5, 2026$694M77 5-pillar Oct 5, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$2.71 Oct 5, 2026$218M73 5-pillar Oct 5, 2026
LB Pharmaceuticals Inc (LBRX) Same industry, near in market value$34.62 Oct 5, 2026$993M69 5-pillar Oct 5, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$11.05 Oct 5, 2026$640M68 5-pillar Oct 5, 2026
Oculis Holding AG (OCS) — this page$8.56$489M23

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$26.00 – $45.00
Consensus target
$36.75
Median target
$38.00
Revenue estimate
$862,272
EPS estimate
$-1.55

Consensus record · Captured .

Measured against a quoted price of $8.56 (as of Oct 5, 2026).

What has been published about Oculis Holding AG (OCS)?

Read these with our analysis →

Oculis Holding AG Stock: Key Questions Answered

These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.

What does the MoonshotScore mean for OCS?

OCS carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is OCS a good stock to buy?

Stock Expert AI does not rate OCS buy, sell or hold. Oculis Holding AG carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the OCS stock price today?

The last price recorded on this page for Oculis Holding AG (OCS) is $8.56, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the OCS price target?

The analyst consensus price target for Oculis Holding AG (OCS) is $36.75 (range $26.00 to $45.00, median $38.00), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the key factors to evaluate for OCS?

Oculis Holding AG (OCS) holds a MoonshotScore in the low range. Analysts target $36.75 (+329%). Timeline: Ongoing, with potential for new partnerships to be established at any time. Not financial advice.

How frequently does OCS data refresh on this page?

OCS's price is the last quote we recorded, from the Oct 5, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven OCS's recent stock price performance?

Oculis Holding AG (OCS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative topical formulations. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider OCS overvalued or undervalued right now?

Oculis Holding AG (OCS) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $36.75 (+329%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of OCS?

Fractional-share availability for Oculis Holding AG (OCS) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources — records for every figure on this page (23 figures)

The 23 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.

"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.

FMP — 12 facts from Financial Modeling Prep endpoint families

FMP facts used on this page
Fact IDFactValue as shownAs ofTierSource
px.lastLatest provided price$8.56FMPFinancial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T22:54:27.857Z.
px.changeChange on the day-1.95%FMPFinancial Modeling Prep (FMP) · quote
px.mcapMarket capitalisation$489MFMPFinancial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-05. FMP quote timestamp: 2026-10-05T20:00:00.000Z. Captured from FMP at 2026-10-05T22:54:26.939Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares.
px.change_absChange on the day, in dollars−$0.17FMPFinancial Modeling Prep (FMP) · quote
fin.q_revenueRevenue, Q3 FY2025$292,236.66FMPFinancial Modeling Prep (FMP) · income statement (quarterly)
px.volumeShares traded on the day242.0KFMPFinancial Modeling Prep (FMP) · quote
fin.q_incomeNet income, Q3 FY2025-$20MFMPFinancial Modeling Prep (FMP) · income statement (quarterly)
fin.q_tableQuarterly income statement1 quarters through Q3 FY2025FMPFinancial Modeling Prep (FMP) · income statement (quarterly), as filed
earn.ptStored analyst price targetslow $26.00 · high $45.00 · consensus $36.75 · median $38.00FMPFinancial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied
earn.pt_rangeAnalyst price target, low to high$26.00 – $45.00FMPFinancial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied
earn.pt_consensusConsensus analyst price target$36.75FMPFinancial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied
earn.pt_medianMedian analyst price target$38.00FMPFinancial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied

UNRECORDED — 9 facts from stored observations whose source was not recorded

UNRECORDED facts used on this page
Fact IDFactValue as shownAs ofTierSource
earn.historyReported versus estimated, recent quartersEPS beat 2 of 8UNRECORDEDStored earnings-history observation — Captured 2026-09-21 · Expired observation
fin.scoresDistress and quality screensAltman Z 5.58 · Piotroski F 4UNRECORDEDStored financial-scores observation — Captured 2026-10-05
px.range5252-week range$9.00 – $34.48UNRECORDEDStored company-profile observation — Captured 2026-09-29
id.employeesEmployees60UNRECORDEDStored company-profile observation — Captured 2026-09-29
id.ceoChief executiveRiad SherifUNRECORDEDStored company-profile observation — Captured 2026-09-29
fin.ratiosReturn and yield ratios (trailing twelve months)ROE -42.9% · ROA -31.8% · current ratio 8.35 · earnings yield -15.1% · free-cash-flow yield -13.4%—UNRECORDEDStored key metrics — Date unknown
earn.estimatesAnalyst estimates, next fiscal yearFY2026 revenue $862,272 · EPS -1.55 · 7 analystsUNRECORDEDStored analyst estimates — Captured 2026-10-05
earn.est_revenueRevenue estimate, FY2026$862,272UNRECORDEDStored analyst estimates — Captured 2026-10-05
earn.est_epsEPS estimate, FY2026$-1.55UNRECORDEDStored analyst estimates — Captured 2026-10-05

OURS — 2 facts from Stock Expert AI's own score and rank

OURS facts used on this page
Fact IDFactValue as shownAs ofTierSource
ours.moonshotMoonshotScore v223 of 100 · Weak · pillars 20 / 78 / 39 / 8 / 19OURSStock Expert AI MoonshotScore v2 engine
ours.moonshot_changeMoonshotScore movement23 (stored snapshot Oct 4, 2026) → 23 (current publication computed Oct 5, 2026) (0)OURSStock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive.
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

ETFs that hold OCS

Funds in our ETF coverage that list OCS among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
GlacierShares Nasdaq Iceland ETF (GLCR)12.32%
Simplify Propel Opportunities ETF (SURI)2.79%